Skip to content
naulon
Not checkedNot checked for notices yet.

Therapeutic effects of Guilu-Erxian-Glue treatment on oligoasthenospermia: Evidence from network pharmacology, molecular docking, and in vivo experimental validation

Jin Ding, Wen Sheng, Baowei Lu and 2 more

Pharmacological Research - Modern Chinese Medicine · 2022

doi:10.1016/j.prmcm.2022.100188 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

ABSTRACT: Oligoasthenospermia (OAS) remains the leading cause of male infertility. Guilu-Erxian-Glue (GLEXG) is a traditional Chinese formula that exhibits beneficial effects in attenuating reproductive dysfunction. However, the mechanism of GLEXG against OAS remains unclear. In this study, we investigated the therapeutic effects of GLEXG against OAS and analyzed its constituents and underlying mechanism. Using the network pharmacology analysis, 40 targets and 53 bioactive compounds of GLXEG associated with OAS were identified, forming a tight disease-drug-compound-target network. IL-6, MYC, CASP3, EGFR, VEGFA, ERBB2, and ESR1 were screened as hub targets in the protein-protein-interaction network. KEGG and GO enrichment analysis and pathway-target-compound network indicated that the HIF-1 signaling pathways were enriched by numerous targets and interact with multiple pathways, including PI3K/Akt and TNF pathway. Molecular docking analysis revealed a tight binding between potential bioactive compounds and hub targets, and the molecular dynamic simulation of the ESR1-Frutinone A complex with the lowest docking energy exhibited high stability. In addition, an OAS rat model was established to determine the therapeutic effects. The results indicated that GLEXG treatment markedly improved sperm quality in the epididymis and reversed histopathological lesions in the testicular tissue, and regulated the expressions of the predicted hub targets and HIF-1α associated with HIF-1 signaling pathway. Our results illustrated the potential therapeutic effects of GLEXG on OAS, suggesting that it is an alternative therapy against OAS.

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.